The White House is betting that a new cash-pay platform—built around blockbuster GLP-1 drugs—can pressure Big Pharma and bypass the middlemen who keep U.S. prices high.
OpenAI and Anthropic released new flagship AI models within hours of each other on Thursday, with benchmark results suggesting they're optimized for different strengths.